Significant response to immunotherapy with atezolizumab has been observed in a group of PSCC patients with high-risk human papillomavirus (HPV) and high infiltration of intratumoral CD3 + CD8 + T cells [6], evidencing the importance of tumor‐infiltrating T lymphocytes in PSCC. This evidence concerns the gene CD8A and neoplasm.